2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MEIER-KRIESCHE, H.-U. Articles by KAPLAN, B. Search for Related Content PubMed PubMed Citation Articles by MEIER-KRIESCHE, H.-U. Articles by KAPLAN, B.

Effect of Mycophenolate Mofetil on Long-Term Outcomes in African American Renal Transplant Recipients

Departments of Medicine and Surgery, University of Michigan, Ann Arbor, Michigan

Correspondence to Dr. Bruce Kaplan, University of Michigan Medical Center, Department of Internal Medicine, 3914 Taubman Center, Box 0364, Ann Arbor, MI 48109-0364. Phone: 734-936-5645; Fax: 734-936-9621; E-mail: brkaplan{at}umich.edu

Abstract. African American renal transplant recipients have poorer graft survival. A study using the United States Renal Data Registry documented an improvement in graft survival for patients who took mycophenolate mofetil (MMF) compared with azathioprine (AZA). This analysis did not address the impact of MMF on African American renal transplant recipients. The present study aimed to quantify potential beneficial effects of MMF therapy on long-term renal allograft survival in African Americans. With the use of the United States Renal Data Registry, all adult Caucasian and African American patients who had received a primary renal transplant between 1988 and 1997 were analyzed by Kaplan-Meier analysis and Cox proportional hazard models. Primary study end points were death with a functioning graft and graft failure censored for death. A total of 57,926 patients were studied. For African Americans, 3-yr patient survival was 96.3 versus 93.2% (P < 0.001) for MMF and AZA, respectively. Three-yr death-censored graft survival for African Americans was 85.8 versus 75.1% (P < 0.001) for MMF and AZA, respectively. For Caucasians, 3-yr patient survival was 97.3 versus 93.2% for MMF and AZA, respectively. Three-yr death-censored graft survival for Caucasians was 90.1 versus 86.4% (P < 0.001) for MMF and AZA, respectively. By multivariate analysis, MMF was associated with a significant reduction in the relative risk for all study end points in African Americans. MMF therapy is associated with both improved patient and death-censored graft survival in African American renal transplant recipients. This benefit is comparable to the benefit of MMF in Caucasian renal transplant recipients.

This article has been cited by other articles:

				P. M. Stirnemann, S. K. Takemoto, M. A. Schnitzler, D. C. Brennan, K. C. Abbott, P. Salvalaggio, T. E. Burroughs, J. A. Gavard, L. M. Willoughby, and K. L. Lentine Agreement of Immunosuppression Regimens Described in Medicare Pharmacy Claims with the Organ Procurement and Transplantation Network Survey J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2299 - 2306. [Abstract] [Full Text] [PDF]

				M. A. Schnitzler, K. E. Craig, K. E. Hardinger, J. A. Lowell, and D. C. Brennan Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation Nephrol. Dial. Transplant., June 1, 2003; 18(6): 1197 - 1200. [Abstract] [Full Text] [PDF]

				K. C. Abbott, L. Y. Agodoa, and P. G. O'Malley Hospitalized Psychoses after Renal Transplantation in the United States: Incidence, Risk Factors, and Prognosis J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1628 - 1635. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673